tetano
Editor, Senior Moderator
J Virol. 2017 Jun 21. pii: JVI.00720-17. doi: 10.1128/JVI.00720-17. [Epub ahead of print]
[h=1]Interplay of PA-X and NS1 proteins in replication and pathogenesis of a temperature-sensitive 2009 pandemic H1N1 influenza A virus.[/h] Nogales A[SUP]1[/SUP], Rodriguez L[SUP]1[/SUP], DeDiego ML[SUP]1,[/SUP][SUP]1[/SUP], Topham DJ[SUP]1,[/SUP][SUP]1[/SUP], Mart?nez-Sobrido L[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A viruses (IAVs) cause seasonal epidemics and occasional pandemics, representing a serious public health concern. It has been described that one mechanism used by some IAV strains to escape the host innate immune responses and modulate virus pathogenicity involves the ability of PA-X and NS1 proteins to inhibit the host protein synthesis in infected cells. It was reported that for the 2009 pandemic H1N1 IAV (pH1N1) only the PA-X protein has this inhibiting capability while the NS1 protein did not. In this work, we have evaluated, for the first time, the combined effect of PA-X- and NS1-mediated inhibition of general gene expression on virus pathogenesis, using a temperature-sensitive, live-attenuated 2009 pandemic H1N1 IAV (pH1N1 LAIV). We found that viruses containing PA-X and NS1 proteins that simultaneously have (PA[SUB]WT[/SUB][SUP]+[/SUP]/NS1[SUB]MUT[/SUB][SUP]+[/SUP]) or do not have (PA[SUB]MUT[/SUB][SUP]-[/SUP]/NS1[SUB]WT[/SUB][SUP]-[/SUP]) the ability to block host gene expression showed reduced pathogenicity in vivo However, a virus where the ability to inhibit host protein expression was switched between PA-X and NS1 (PA[SUB]MUT[/SUB][SUP]-[/SUP]/NS1[SUB]MUT[/SUB][SUP]+[/SUP]) presented similar pathogenicity to a virus containing both wild-type proteins (PA[SUB]WT[/SUB][SUP]+[/SUP]/NS1[SUB]WT[/SUB][SUP]-[/SUP]). Our findings suggest that inhibition of host protein expression is subject to a strict balance, which can determine the successful progression of IAV infection. Importantly, knowledge obtained from our studies could be used for the development of new and more effective vaccine approaches against IAV.IMPORTANCE Influenza A viruses (IAVs) are one of the most common causes of respiratory infections in humans, resulting in thousands of deaths annually. Furthermore, IAVs can cause unpredictable pandemics of great consequence when viruses not previously circulating in humans are introduced into humans. The defense machinery provided by the host innate immune system limits IAV replication; however, to counteract host antiviral activities, IAVs have developed different inhibition mechanisms, including prevention of host gene expression mediated by the viral PA-X and NS1 proteins. Here, we provide evidence demonstrating that optimal control of host protein synthesis by IAV PA-X and/or NS1 proteins is required for efficient IAV replication in the host. Moreover, we demonstrate the feasibility of genetically controlling the ability of IAV PA-X and NS1 proteins to inhibit host immune responses, providing an approach to develop more effective vaccines to combat disease caused by this important respiratory pathogen.
Copyright ? 2017 American Society for Microbiology.
PMID: 28637750 DOI: 10.1128/JVI.00720-17
[h=1]Interplay of PA-X and NS1 proteins in replication and pathogenesis of a temperature-sensitive 2009 pandemic H1N1 influenza A virus.[/h] Nogales A[SUP]1[/SUP], Rodriguez L[SUP]1[/SUP], DeDiego ML[SUP]1,[/SUP][SUP]1[/SUP], Topham DJ[SUP]1,[/SUP][SUP]1[/SUP], Mart?nez-Sobrido L[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A viruses (IAVs) cause seasonal epidemics and occasional pandemics, representing a serious public health concern. It has been described that one mechanism used by some IAV strains to escape the host innate immune responses and modulate virus pathogenicity involves the ability of PA-X and NS1 proteins to inhibit the host protein synthesis in infected cells. It was reported that for the 2009 pandemic H1N1 IAV (pH1N1) only the PA-X protein has this inhibiting capability while the NS1 protein did not. In this work, we have evaluated, for the first time, the combined effect of PA-X- and NS1-mediated inhibition of general gene expression on virus pathogenesis, using a temperature-sensitive, live-attenuated 2009 pandemic H1N1 IAV (pH1N1 LAIV). We found that viruses containing PA-X and NS1 proteins that simultaneously have (PA[SUB]WT[/SUB][SUP]+[/SUP]/NS1[SUB]MUT[/SUB][SUP]+[/SUP]) or do not have (PA[SUB]MUT[/SUB][SUP]-[/SUP]/NS1[SUB]WT[/SUB][SUP]-[/SUP]) the ability to block host gene expression showed reduced pathogenicity in vivo However, a virus where the ability to inhibit host protein expression was switched between PA-X and NS1 (PA[SUB]MUT[/SUB][SUP]-[/SUP]/NS1[SUB]MUT[/SUB][SUP]+[/SUP]) presented similar pathogenicity to a virus containing both wild-type proteins (PA[SUB]WT[/SUB][SUP]+[/SUP]/NS1[SUB]WT[/SUB][SUP]-[/SUP]). Our findings suggest that inhibition of host protein expression is subject to a strict balance, which can determine the successful progression of IAV infection. Importantly, knowledge obtained from our studies could be used for the development of new and more effective vaccine approaches against IAV.IMPORTANCE Influenza A viruses (IAVs) are one of the most common causes of respiratory infections in humans, resulting in thousands of deaths annually. Furthermore, IAVs can cause unpredictable pandemics of great consequence when viruses not previously circulating in humans are introduced into humans. The defense machinery provided by the host innate immune system limits IAV replication; however, to counteract host antiviral activities, IAVs have developed different inhibition mechanisms, including prevention of host gene expression mediated by the viral PA-X and NS1 proteins. Here, we provide evidence demonstrating that optimal control of host protein synthesis by IAV PA-X and/or NS1 proteins is required for efficient IAV replication in the host. Moreover, we demonstrate the feasibility of genetically controlling the ability of IAV PA-X and NS1 proteins to inhibit host immune responses, providing an approach to develop more effective vaccines to combat disease caused by this important respiratory pathogen.
Copyright ? 2017 American Society for Microbiology.
PMID: 28637750 DOI: 10.1128/JVI.00720-17